Method of determining the time to progression of non small cell lung cancer after chemotherapy based on thioredoxin expression

Details for Australian Patent Application No. 2008250284 (hide)

Owner Pangaea Biotech, S.A.

Inventors Rosell Costa, Rafael; Taron Roca, Miguel

Agent Fisher Adams Kelly

Pub. Number AU-A-2008250284

PCT Pub. Number WO2008/138880

Priority 07107960.2 10.05.07 EP

Filing date 9 May 2008

Wipo publication date 20 November 2008

International Classifications

C12Q 1/68 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving nucleic acids

G01N 33/574 (2006.01) Investigating or analysing materials by specific methods not covered by groups - for cancer

Event Publications

3 December 2009 PCT application entered the National Phase

  PCT publication WO2008/138880 Priority application(s): WO2008/138880

17 May 2012 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008250293-3, 6-disubstituted-imidazo [1, 2-b] pyridazines and 3, 5-disubstituted pyrazolo[1, 5-a] pyrimidines as phosphatidylinositol-3-kinase inhibitors

2008250282-Novel pyridopyrazine derivatives, process of manufacturing and uses thereof